Anixa Biosciences announced progress in its ovarian cancer CAR-T therapy, lira-cel, now at the highest dose level in its Phase 1 trial with lymphodepletion, showing no dose-limiting toxicities and four patients surviving over one year, the longest about 28 months. Additionally, their breast cancer vaccine completed Phase 1 trials meeting all primary endpoints with immune responses in 74% of participants, and preparations for Phase 2 are underway. These advancements highlight Anixa's collaboration with leading cancer research centers like Moffitt Cancer Center and Cleveland Clinic, signaling potential new treatment options for resistant ovarian and breast cancers. Management will present these updates at the H.C. Wainwright Annual Global Investment Conference in September 2026.
Intel shares fell 4% alongside other chipmakers like AMD and NVIDIA due to rising Treasury yields pressuring high-growth tech stocks. Despite the pullback, Intel stock is still up 180% year-to-date. Recent quarterly filings revealed NVIDIA holds a ma...
Amazon's stock has risen over 15% following a record Q2 performance, with Morgan Stanley analyst Brian Nowak reiterating a 'Buy' rating and setting a 12-month price target of $335, implying a 28.6% potential gain. The firm also forecasts a long-term ...
CEO.CA, a leading investor social network for junior resource stocks, features an exclusive interview with Victor Cantore, CEO of AMEX Gold Mining Inc. The discussion highlights AMEX's progress in transforming its Perron Project in Quebec from a prom...
Meta Platforms has seen its stock drop about 27% year-to-date, underperforming the broader market. This decline is largely due to one-time legal and severance costs that have compressed margins and caused earnings misses. However, these charges are e...
NewLake Capital Partners (NLCP) has effectively managed tenant defaults through a strategy focusing on credit-worthy cannabis tenants and four-wall leases, resulting in 100% rental collection and a healthy balance sheet. This has supported secure div...
